Leah Kuntz

What are the most important psychiatric advancements and insights from 2025? Share with us!

Check out the pipeline updates from November!

Discover the latest insights from Southern Florida Psychiatry Conference on stuttering, its neurological basis, and innovative treatment approaches to improve quality of life for those affected.

Vagus nerve stimulation offers a promising solution for treatment-resistant depression, showcasing significant long-term efficacy and durability in patients.

Experts at the Southern Florida Psychiatry Conference emphasize the importance of screening for postpartum depression, highlighting effective treatments and support strategies for new mothers' mental health.

Digital therapeutics revolutionize health care by enhancing patient outcomes through technology and offering scalable, evidence-based treatments for various conditions.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

New research reveals hyperbaric oxygen therapy as a promising treatment for chronic PTSD, enhancing brain function and providing lasting symptom relief.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

Axsome Therapeutics advances AXS-05 for Alzheimer disease agitation, showing significant improvement in clinical trials and addressing critical patient needs.

Share your innovative best practices that enhance patient care!

Halloween poses unique challenges for individuals with mental health disorders, but strategies exist to help them navigate the spooky season safely.

Check out the pipeline updates from October!

Cingulate's CTx-1301 shows promising phase 3 results for ADHD, offering effective once-daily dosing and potential FDA approval by 2026.

Laguna Diagnostics revolutionizes psychiatric interventions with patented blood tests that accurately diagnose schizophrenia and bipolar disorder.

New analysis reveals Ingrezza's 40 mg dose significantly improves tardive dyskinesia symptoms, showcasing long-term efficacy and safety in patients.

Discover how best to approach ADHD assessments and utilize tools such as the Mentavi Diagnostic Evaluation, which can help improve patient care and reduce stigma.

Uzedy, a once-monthly extended release long-acting injectable, is now FDA approved for bipolar I disorder.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.

Esketamine nasal spray shows significant improvements in treatment-resistant depression, with effective dose management and minimal adverse effects in recent studies.